Combining anti-TNF-α and vedolizumab in the treatment of inflammatory bowel disease: a case series

LCT Buer, ML Høivik, DJ Warren… - Inflammatory Bowel …, 2018 - academic.oup.com
Background Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of
inflammatory bowel disease, but some patients experience only a partial response. In these …
被引用次数：57 相关文章

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series

LCT Buer, ML Høivik, DJ Warren… - Inflammatory Bowel …, 2018 - academic.oup.com
Background Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of
inflammatory bowel disease, but some patients experience only a partial response. In these …

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series.

LCT Buer, ML Høivik, DJ Warren… - Inflammatory Bowel …, 2018 - europepmc.org
Background Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of
inflammatory bowel disease, but some patients experience only a partial response. In these …

[引用][C] Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series

LCT Buer, ML Høivik, DJ Warren, AW Medhus… - Inflammatory Bowel …, 2018 - cir.nii.ac.jp
Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A
Case Series | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series

LCT Buer, ML Høivik, DJ Warren… - Inflammatory …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of
inflammatory bowel disease, but some patients experience only a partial response. In these …